Abstract: A UE transmits a registration request message including an S-NSSAI and receives a registration accept message including the S-NSSAI, a first cause value, and a first back-off timer value. The UE starts a back-off timer using the first back-off timer value corresponding to the S-NSSAI. In a case that the UE receives a configuration update command including the S-NSSAI, a second cause value, and a second back-off timer value before expiration of the back-off timer, the UE updates, in a case that the second back-off timer value indicates a value other than zero the back-off timer to be the second back-off timer value and stops, in a case that the second back-off timer value indicates zero, the back-off timer. In a case that the back-off timer expires or stops, the UE transmits the registration request message including the S-NSSAI or a PDU session establishment request message.

Abstract: The present invention provides a method for multiproduct resin reuse (MRR) utilizing ionic exchange chromatography columns. The methods of the invention outline the cleaning steps necessary for reuse as well as the analytical processes used in determining product carryover from production of one product to the next. The invention outlines a successful MRR strategy that can be utilized not just in lab-scale studies, but in a GMP manufacturing setting.

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

Abstract: The present invention is directed to cyclobutyl pyrazolopyrimidine compounds which may be useful as therapeutic agents for the treatment of disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating cardiovascular and cerebrovascular diseases, such as hypertension, chronic kidney disease and heart failure, and neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Abstract: A base station apparatus for communicating with a terminal apparatus transmits a Radio Resource Control (RRC) connection reconfiguration request message including a Data Radio Bearer (DRB) configuration to the terminal apparatus. The DRB configuration includes a DRB identity and a Packet Data Convergence Protocol Layer (PDCP) entity configuration corresponding to the DRB identity. PDCP entity configuration information includes one of a PDCP entity configuration for Evolved Universal Terrestrial Radio Access (E-UTRA) and a PDCP entity configuration for New Radio (NR). A PDCP entity is established in accordance with the PDCP entity configuration information.

Abstract: An image display device is provided that allows easy adjustment of positional deviation in an optical axis direction of an optical modulation element from the outside. The image display device includes: a housing including an operation surface; an optical modulation element that is housed in the housing and that includes an image-forming surface that modulates light to form an image; a holding portion that movably holds the optical modulation element at least in a direction perpendicular to the image-forming surface; and an adjusting portion including at least one wire member, one end of the wire member being connected to the holding portion and the other end rotatably attached to the operation surface. Holding portion includes a movable portion that is moved in a direction perpendicular to the image-forming surface by the rotation of the other end of the wire member.

Abstract: Disclosed are compounds of Formula (I), Formula (II), or a salt thereof: Formula (I) Formula (II) which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula (I), Formula (II) or their salts, and methods of treating pain disorders, cough, and itch using the same.

Abstract: Systems and methods relate to display of insights, including a method including: causing a user display to display a graphical user interface (GUI) that enables a user to select a time range and a single digital display as a locale; and causing, based on the user selecting the time range and the single digital display as the locale, the user display to display, on the GUI, a list of a plurality of media content that have been displayed on the single digital display, each of the plurality of media content being ordered according to analysis insight for the single digital display selected and the time range selected. The analysis insight may include at least opportunity to see (OTS) counts of the plurality of media content on one or more digital displays associated with the locale.

Abstract: The present invention is directed to methods for inhibition of HIV reverse transcriptase, treatment of infection by HIV, prophylaxis of infection by HIV, and the treatment, prophylaxis and/or delay in the onset or progression of AIDS or ARC by administering a compound of structural Formula I or a pharmaceutically acceptable salt or co-crystal thereof, wherein X is —F or —Cl, less frequently than once daily.

Abstract: The invention relates to methods for treating cancer in a patient comprising subcutaneously administering a PD-1 antagonist, e.g., an anti-PD-1 antibody, or antigen binding fragment thereof, (e.g. pembrolizumab), in specific amounts to the patient. In some embodiments, the administration occurs about every three weeks. In some embodiments, the amount of anti-PD-1 antibody, or antigen binding fragment thereof, is about 280 mg to about 450 mg. In certain embodiments, the PD-1 antagonist is pembrolizumab, or an antigen binding fragment thereof. Also provided are compositions and kits formulated for subcutaneous administration comprising a dosage of an anti-PD-1 antibody, or antigen-binding fragment thereof, and uses thereof for treating cancer.

Abstract: The invention relates to stable formulations comprising antibodies or antigen binding fragments thereof that bind to cytotoxic T lymphocyte associated antigen 4 (CTLA4), optionally further containing an anti-human programmed death receptor 1 (PD-1) antibody or antigen binding fragment thereof. Also provided are methods of treating various cancers and chronic infections with the formulations of the invention.

Abstract: The present disclosure provides a control method in user equipment and user equipment. The control method in user equipment includes: transmitting, to a base station, a Radio Resource Control (RRC) connection reestablishment request message for requesting RRC connection reestablishment; receiving an RRC connection reestablishment response message transmitted by the base station as a response to the RRC connection reestablishment request message; when the RRC connection reestablishment response message indicates that RRC connection reestablishment is performed, a UE RRC layer performs an RRC connection reestablishment operation; and when the RRC connection reestablishment response message is an RRC connection establishment message used to instruct the UE to establish a new RRC connection, the UE RRC layer performs an RRC connection establishment operation, and a UE NAS layer initiates an NAS connection recovery procedure.

Abstract: According to an aspect of the present invention, a procedure and a communicator for initial registration of UE or periodic or mobility-based registration for achieving Network Slice Specific Authentication and Authorization in 5GS. Furthermore, a communicator for achieving a function related to Network Slice Specific Authentication and Authorization in 5GS is provided by providing a procedure and a communicator for changing a UE configuration initiated by a network, the procedure being initiated based on the Network Slice Specific Authentication and Authorization initiated by the network and completion of the Network Slice Specific Authentication and Authorization.

Abstract: An image display element includes pixels, a driving circuit substrate, a microlens, and an inter-pixel partition. The pixels are disposed in an array, each including a micro light emitting element. The driving circuit substrate includes a driving circuit configured to supply a current to the micro light emitting element and cause the micro light emitting element to emit light. The microlens is disposed for each of the pixels. The inter-pixel partition is disposed between the pixels and extends from a light emitting surface of the micro light emitting element to the microlens.

Abstract: Described herein are compounds of Formula (I), or a pharmaceutically acceptable salt thereof. The compounds of Formula (I) act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases.

Abstract: An ink composition for ink-jet printing includes a functional material and an alkylene glycol derivative, wherein the functional material includes OTPD.

Abstract: A method performed by a UE is provided. The method includes receiving at least one SL-DRX configuration and a plurality of SL resource pool configurations to be configured on the first UE; performing partial sensing based on at least one of the plurality of SL resource pool configurations when an SL-DRX operation is performed based on the at least one SL-DRX configuration, each of at least one SL resource pool configured by the at least one of the plurality of SL resource pool configurations comprising one or more time slots; and performing SL-CBR measurement associated with each of the at least one SL resource pool in the one or more time slots where the partial sensing is performed.

Abstract: An active matrix substrate includes a substrate in which a notch or an aperture is formed, and electrodes. Each electrode includes at least either of: a capacitor forming portion that is arranged in a region other than a bypass region and overlaps with at least one of a plurality of bypass gate lines when viewed in a plan view; and an electrode layer portion that is formed in an electrode layer and that composes a bypass gate line interposed portion together with a source line layer portion formed in a source line layer in the bypass region. The electrode layer portion and the source line layer portion overlap with at least one of the bypass gate lines in the bypass region when viewed in a plan view, and at least one of the bypass gate lines is positioned between the electrode layer portion and the source line layer portion in a normal line direction of the substrate.

Abstract: An image forming apparatus includes: an operation acceptor that accepts an operation; an image former that has, to be switchable, two image formation modes that are a normal mode and a silent mode; one or more controllers; and one or more power-source controllers that control a power source, the power-source controllers transitioning to a predetermined sleep state when the operation acceptor has not accepted an operation for a predetermined standby time, and transitioning to a predetermined shutoff state when the operation acceptor has not accepted an operation for a predetermined sleep time, the controllers control the power-source controllers to transition to the shutoff state when a predetermined first sleep time has elapsed, and after transitioning to the sleep state during the silent mode, the controllers control the power-source controllers to transition to the shutoff state when a predetermined second sleep time has elapsed.

Abstract: This light-emitting device includes: a light-emitting diode including a light-emitting layer of quantum dots or an organic light-emitting material; and a protection diode located adjacent to, and connected in parallel with, the light-emitting diode, wherein the protection diode is operated in reverse bias to protect the light-emitting diode.